Stage 2+ or Stage 3+ Retinopathy of Prematurity in Zone I or Zone II. Clinical Trial
Prospective study to evaluate the efficacy and safety of intravitreal bevacizumab In
retinopathy of prematurity (ROP).
Bevacizumab 0.75 mg in 0.03 ml was given to stage 2+ or stage 3+ ROP in Zone I or Zone II.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | December 2012 |
Est. primary completion date | December 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 32 Weeks to 42 Weeks |
Eligibility |
Inclusion Criteria: stage 2+ or stage 3+ Retinopathy of prematurity in Zone I or Zone II. Informed written consent by parents or guardian. Exclusion Criteria: Refusal to give consent Critically ill neonates. |
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United Arab Emirates | Dubai Hospital | Dubai | UAE |
Lead Sponsor | Collaborator |
---|---|
Sivakami A Pai |
United Arab Emirates,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Regression Of ROP | Minimum 6 months follow up after intravitreal Avastin | Yes | |
Secondary | Recurrence of ROP | minimum 6 months of follow up. | Yes |